{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:00:01Z","timestamp":1785128401582,"version":"3.55.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T00:00:00Z","timestamp":1353542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00213-012-2922-7","type":"journal-article","created":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T19:24:59Z","timestamp":1353612299000},"page":"505-518","source":"Crossref","is-referenced-by-count":91,"title":["Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?"],"prefix":"10.1007","volume":"225","author":[{"given":"Gary","family":"Remington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Agid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Foussias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krysta","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,22]]},"reference":[{"key":"2922_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.161.1.1","volume":"161","author":"American Psychiatric Association","year":"2004","unstructured":"American Psychiatric Association (2004) Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 161:1\u201356","journal-title":"Am J Psychiatry"},{"key":"2922_CR2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4088\/JCP.v58n1106h","volume":"58","author":"SC Armstrong","year":"1997","unstructured":"Armstrong SC, Stephans JR (1997) Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage. J Clin Psychiatry 58:499","journal-title":"J Clin Psychiatry"},{"key":"2922_CR3","first-page":"20","volume":"41","author":"R Bedry","year":"1999","unstructured":"Bedry R, Deschamps L, Pehourcq F, Moore N, Pillet O, Favarel-Garrigues JC (1999) Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. Vet Hum Toxicol 41:20\u201322","journal-title":"Vet Hum Toxicol"},{"key":"2922_CR4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/00048679809068332","volume":"32","author":"R Bell","year":"1998","unstructured":"Bell R, McLaren A, Galanos J, Copolov D (1998) The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 32:567\u2013574","journal-title":"Aust N Z J Psychiatry"},{"key":"2922_CR5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","volume":"155","author":"G Bondolfi","year":"1998","unstructured":"Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 155:499\u2013504","journal-title":"Am J Psychiatry"},{"key":"2922_CR6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/schbul\/16.4.551","volume":"16","author":"HD Brenner","year":"1990","unstructured":"Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK (1990) Defining treatment refractoriness in schizophrenia. Schizophr Bull 16:551\u2013561","journal-title":"Schizophr Bull"},{"key":"2922_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-2007-979318","volume":"31","author":"K Broich","year":"1998","unstructured":"Broich K, Heinrich S, Marneros A (1998) Acute clozapine overdose: plasma concentration and outcome. Pharmacopsychiatry 31:149\u2013151","journal-title":"Pharmacopsychiatry"},{"key":"2922_CR8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/0044011-200929010-00006","volume":"29","author":"EE Brouwers","year":"2009","unstructured":"Brouwers EE, Sohne M, Kuipers S, van Gorp EC, Schellens JH, Koks CH, Beijnen JH, Huitema AD (2009) Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 29:59\u201363","journal-title":"Clin Drug Investig"},{"key":"2922_CR9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-9964(99)00084-5","volume":"49","author":"PF Buckley","year":"2001","unstructured":"Buckley PF, Friedman L, Krowinski AC, Eaton Y, Tronetti M, Miller DD (2001) Clinical and biochemical correlates of \u201chigh-dose\u201d clozapine therapy for treatment-refractory schizophrenia. Schizophr Res 49:225\u2013227","journal-title":"Schizophr Res"},{"key":"2922_CR10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0924-977X(99)00033-4","volume":"9","author":"B Buur-Rasmussen","year":"1999","unstructured":"Buur-Rasmussen B, Brosen K (1999) Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 9:453\u2013459","journal-title":"Eur Neuropsychopharmacol"},{"key":"2922_CR11","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1177\/070674370505000101","volume":"50","author":"Canadian Psychiatric Association","year":"2005","unstructured":"Canadian Psychiatric Association (2005) Clinical practice guidelines: treatment for schizophrenia. Can J Psychiatry 50:1S\u201356S","journal-title":"Can J Psychiatry"},{"key":"2922_CR12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.152.4.610","volume":"152","author":"F Centorrino","year":"1995","unstructured":"Centorrino F, Baldessarini RJ, Flood JG, Kando JC, Frankenburg FR (1995) Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry 152:610\u2013612","journal-title":"Am J Psychiatry"},{"key":"2922_CR13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ajp.151.1.123","volume":"151","author":"F Centorrino","year":"1994","unstructured":"Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG (1994a) Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 151:123\u2013125","journal-title":"Am J Psychiatry"},{"key":"2922_CR14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004714-199404000-00006","volume":"14","author":"F Centorrino","year":"1994","unstructured":"Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG (1994b) Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 14:119\u2013125","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002130051036","volume":"145","author":"WH Chang","year":"1999","unstructured":"Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, Jann MW (1999) In-vitro and in-vivo evaluation of the drug\u2013drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl) 145:91\u201398","journal-title":"Psychopharmacology (Berl)"},{"key":"2922_CR16","first-page":"75","volume":"29","author":"SA Chong","year":"2000","unstructured":"Chong SA, Remington GJ, Lee N, Mahendran R (2000) Contrasting clozapine prescribing patterns in the east and west? Ann Acad Med Singapore 29:75\u201378","journal-title":"Ann Acad Med Singapore"},{"key":"2922_CR17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00004714-199702000-00024","volume":"17","author":"SA Chong","year":"1997","unstructured":"Chong SA, Tan CH, Lee HS (1997) Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 17:68\u201369","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archinte.1996.00440060103013","volume":"156","author":"LG Cohen","year":"1996","unstructured":"Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC (1996) Erythromycin-induced clozapine toxic reaction. Arch Intern Med 156:675\u2013677","journal-title":"Arch Intern Med"},{"key":"2922_CR19","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/j.1875-9114.1997.tb03096.x","volume":"17","author":"MD Combs","year":"1997","unstructured":"Combs MD, Perry PJ, Bever KA (1997) N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy 17:1300\u20131304","journal-title":"Pharmacotherapy"},{"key":"2922_CR20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02326373","volume":"67","author":"TB Cooper","year":"1996","unstructured":"Cooper TB (1996) Clozapine plasma level monitoring: current status. Psychiatr Q 67:297\u2013311","journal-title":"Psychiatr Q"},{"key":"2922_CR21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","volume":"32","author":"L Couchman","year":"2010","unstructured":"Couchman L, Morgan PE, Spencer EP, Flanagan RJ (2010) Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993\u20132007. Ther Drug Monit 32:438\u2013447","journal-title":"Ther Drug Monit"},{"key":"2922_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","volume":"18","author":"J Crilly","year":"2007","unstructured":"Crilly J (2007) The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 18:39\u201360","journal-title":"Hist Psychiatry"},{"key":"2922_CR23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3371\/CSRP.5.3.7","volume":"5","author":"P Darling","year":"2011","unstructured":"Darling P, Huthwaite MA (2011) Infection-associated clozapine toxicity. Clin Schizophr Relat Psychoses 5:159\u2013160","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"2922_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157488612800492681","volume":"7","author":"D Berardis De","year":"2012","unstructured":"De Berardis D, Serroni N, Campanella D, Olivieri L, Ferri F, Carano A, Cavuto M, Martinotti G, Cicconetti A, Piersanti M, Saverio Moschetta F, Di Giannantonio M (2012) Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 7:55\u201362","journal-title":"Curr Drug Saf"},{"key":"2922_CR25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0278-5846(03)00148-9","volume":"27","author":"J Leon de","year":"2003","unstructured":"de Leon J, Diaz FJ (2003) Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry 27:1059\u20131063","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2922_CR26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.jcp.0000085405.08426.73","volume":"23","author":"J Leon de","year":"2003","unstructured":"de Leon J, Odom-White A, Josiassen RC, Diaz FJ, Cooper TB, Simpson GM (2003) Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol 23:336\u2013341","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR27","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1176\/appi.ajp.159.7.1243-a","volume":"159","author":"JR Dequardo","year":"2002","unstructured":"Dequardo JR (2002) Modafinil-associated clozapine toxicity. Am J Psychiatry 159:1243\u20131244","journal-title":"Am J Psychiatry"},{"key":"2922_CR28","first-page":"840","volume":"153","author":"JR Dequardo","year":"1996","unstructured":"Dequardo JR, Roberts M (1996) Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 153:840\u2013841","journal-title":"Am J Psychiatry"},{"key":"2922_CR29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.mjt.0000146622.59764.dd","volume":"12","author":"JL Derenne","year":"2005","unstructured":"Derenne JL, Baldessarini RJ (2005) Clozapine toxicity associated with smoking cessation: case report. Am J Ther 12:469\u2013471","journal-title":"Am J Ther"},{"key":"2922_CR30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1212\/WNL.41.3.369","volume":"41","author":"O Devinsky","year":"1991","unstructured":"Devinsky O, Honigfeld G, Patin J (1991) Clozapine-related seizures. Neurology 41:369\u2013371","journal-title":"Neurology"},{"key":"2922_CR31","first-page":"738","volume":"153","author":"G DuMortier","year":"1996","unstructured":"DuMortier G, Lochu A, Colen de Melo P, Ghribi O, Roche-Rabreau D, DeGrassat K, Desce JM (1996) Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 153:738\u2013739","journal-title":"Am J Psychiatry"},{"key":"2922_CR32","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/00004714-200012000-00024","volume":"20","author":"M Fabrazzo","year":"2000","unstructured":"Fabrazzo M, La Pia S, Monteleone P, Mennella R, Esposito G, Pinto A, Maj M (2000) Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol 20:708\u2013710","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1192\/bjp.bp.110.085340","volume":"199","author":"S Farooq","year":"2011","unstructured":"Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, Naeem F (2011) Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). Br J Psychiatry 199:467\u2013472","journal-title":"Br J Psychiatry"},{"key":"2922_CR34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1192\/bjp.bp.110.088690","volume":"198","author":"S Farooq","year":"2011","unstructured":"Farooq S, Taylor M (2011) Clozapine: dangerous orphan or neglected friend? Br J Psychiatry 198:247\u2013249","journal-title":"Br J Psychiatry"},{"key":"2922_CR35","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1520\/JFS14363J","volume":"43","author":"KE Ferslew","year":"1998","unstructured":"Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF (1998) A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 43:1082\u20131085","journal-title":"J Forensic Sci"},{"key":"2922_CR36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.forsciint.2004.10.024","volume":"155","author":"RJ Flanagan","year":"2005","unstructured":"Flanagan RJ, Spencer EP, Morgan PE, Barnes TR, Dunk L (2005) Suspected clozapine poisoning in the UK\/Eire, 1992\u20132003. Forensic Sci Int 155:91\u201399","journal-title":"Forensic Sci Int"},{"key":"2922_CR37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-199732020-00001","volume":"32","author":"DJ Freeman","year":"1997","unstructured":"Freeman DJ, Oyewumi LK (1997) Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 32:93\u2013100","journal-title":"Clin Pharmacokinet"},{"key":"2922_CR38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0006-3223(96)00298-3","volume":"42","author":"O Freudenreich","year":"1997","unstructured":"Freudenreich O, Weiner RD, McEvoy JP (1997) Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 42:132\u2013137","journal-title":"Biol Psychiatry"},{"key":"2922_CR39","first-page":"1840","volume":"151","author":"LG Funderburg","year":"1994","unstructured":"Funderburg LG, Vertrees JE, True JE, Miller AL (1994) Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 151:1840\u20131841","journal-title":"Am J Psychiatry"},{"key":"2922_CR40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0269881103017002014","volume":"17","author":"C Greenwood-Smith","year":"2003","unstructured":"Greenwood-Smith C, Lubman DI, Castle DJ (2003) Serum clozapine levels: a review of their clinical utility. J Psychopharmacol 17:234\u2013238","journal-title":"J Psychopharmacol"},{"key":"2922_CR41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00004714-199812000-00010","volume":"18","author":"C Guitton","year":"1998","unstructured":"Guitton C, Abbar M, Kinowski JM, Chabrand P, Bressolle F (1998) Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 18:470\u2013476","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/00912709922008245","volume":"39","author":"C Guitton","year":"1999","unstructured":"Guitton C, Kinowski JM, Abbar M, Chabrand P, Bressolle F (1999) Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol 39:721\u2013728","journal-title":"J Clin Pharmacol"},{"key":"2922_CR43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0924-977X(03)00042-7","volume":"13","author":"MJ Haack","year":"2003","unstructured":"Haack MJ, Bak ML, Beurskens R, Maes M, Stolk LM, Delespaul PA (2003) Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol 13:381\u2013385","journal-title":"Eur Neuropsychopharmacol"},{"key":"2922_CR44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02245449","volume":"114","author":"C Haring","year":"1994","unstructured":"Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker WW (1994) EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology (Berl) 114:97\u2013100","journal-title":"Psychopharmacology (Berl)"},{"key":"2922_CR45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11096-010-9398-5","volume":"32","author":"J Harrison","year":"2010","unstructured":"Harrison J, Janlov M, Wheeler AJ (2010) Patterns of clozapine prescribing in a mental health service in New Zealand. Pharm World Sci 32:503\u2013511","journal-title":"Pharm World Sci"},{"key":"2922_CR46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00004714-199312000-00003","volume":"13","author":"M Hasegawa","year":"1993","unstructured":"Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY (1993) Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13:383\u2013390","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1008748110692","volume":"21","author":"M Heeringa","year":"1999","unstructured":"Heeringa M, Beurskens R, Schouten W, Verduijn MM (1999) Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 21:243\u2013244","journal-title":"Pharm World Sci"},{"key":"2922_CR48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44:195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"2922_CR49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","volume":"14","author":"C Hiemke","year":"1994","unstructured":"Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279\u2013281","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR50","first-page":"35","volume":"14","author":"GB Hung","year":"2008","unstructured":"Hung GB, Cheung HK (2008) Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong. Hong Kong Med J 14:35\u201339","journal-title":"Hong Kong Med J"},{"key":"2922_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"2922_CR52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-199324020-00005","volume":"24","author":"MW Jann","year":"1993","unstructured":"Jann MW, Grimsley SR, Gray EC, Chang WH (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161\u2013176","journal-title":"Clin Pharmacokinet"},{"key":"2922_CR53","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00228-004-0867-4","volume":"60","author":"J Jecel","year":"2005","unstructured":"Jecel J, Michel TM, Gutknecht L, Schmidt D, Pfuhlmann B, Jabs BE (2005) Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol 60:909\u2013910","journal-title":"Eur J Clin Pharmacol"},{"key":"2922_CR54","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","volume":"16","author":"M Jerling","year":"1994","unstructured":"Jerling M, Lindstrom L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368\u2013374","journal-title":"Ther Drug Monit"},{"key":"2922_CR55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 9","key":"2922_CR56","first-page":"35","volume":"57","author":"JM Kane","year":"1996","unstructured":"Kane JM (1996) Treatment-resistant schizophrenic patients. J Clin Psychiatry 57(Suppl 9):35\u201340","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"2922_CR57","first-page":"5","volume":"64","author":"JM Kane","year":"2003","unstructured":"Kane JM, Leucht S, Carpenter D, Docherty JP (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64(12):5\u201319","journal-title":"J Clin Psychiatry"},{"key":"2922_CR58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/YCT.0b013e3181a2f867","volume":"25","author":"S Keller","year":"2009","unstructured":"Keller S, Drexler H, Lichtenberg P (2009) Very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia. J ECT 25:280\u2013281","journal-title":"J ECT"},{"key":"2922_CR59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00131746-200509000-00003","volume":"11","author":"AY Khan","year":"2005","unstructured":"Khan AY, Preskorn SH (2005) Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 11:289\u2013301","journal-title":"J Psychiatr Pract"},{"key":"2922_CR60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0924-977X(95)00069-2","volume":"6","author":"HJ Koponen","year":"1996","unstructured":"Koponen HJ, Leinonen E, Lepola U (1996) Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 6:69\u201371","journal-title":"Eur Neuropsychopharmacol"},{"key":"2922_CR61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.152.2.179","volume":"152","author":"MH Kronig","year":"1995","unstructured":"Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152:179\u2013182","journal-title":"Am J Psychiatry"},{"key":"2922_CR62","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00004714-199812000-00013","volume":"18","author":"FJ Kuo","year":"1998","unstructured":"Kuo FJ, Lane HY, Chang WH (1998) Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol 18:483\u2013484","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR63","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","volume":"151","author":"JA Lieberman","year":"1994","unstructured":"Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151:1744\u20131752","journal-title":"Am J Psychiatry"},{"key":"2922_CR64","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007691-199604000-00015","volume":"18","author":"HC Liu","year":"1996","unstructured":"Liu HC, Chang WH, Wei FC, Lin SK, Jann MW (1996) Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 18:200\u2013207","journal-title":"Ther Drug Monit"},{"key":"2922_CR65","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0269881108089819","volume":"23","author":"C Maccall","year":"2009","unstructured":"Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer E, Flanagan R (2009) Clozapine: more than 900\u00a0mg\/day may be needed. J Psychopharmacol 23:206\u2013210","journal-title":"J Psychopharmacol"},{"key":"2922_CR66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-9964(03)00159-2","volume":"66","author":"M Mauri","year":"2004","unstructured":"Mauri M, Volonteri LS, Fiorentini A, Invernizzi G, Nerini T, Baldi M, Bareggi SR (2004) Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res 66:197\u2013198","journal-title":"Schizophr Res"},{"key":"2922_CR67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s002130050628","volume":"137","author":"MC Mauri","year":"1998","unstructured":"Mauri MC, Rudelli R, Bravin S, Gianetti S, Giuliani E, Guerrini A, Orlandi R, Invernizzi G (1998) Clozapine metabolism rate as a possible index of drug-induced granulocytopenia. Psychopharmacology (Berl) 137:341\u2013344","journal-title":"Psychopharmacology (Berl)"},{"key":"2922_CR68","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","volume":"46","author":"MC Mauri","year":"2007","unstructured":"Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007) Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46:359\u2013388","journal-title":"Clin Pharmacokinet"},{"key":"2922_CR69","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/01.jcp.0000095351.32154.3a","volume":"23","author":"MC Mauri","year":"2003","unstructured":"Mauri MC, Volonteri LS, Dell\u2019Osso B, Regispani F, Papa P, Baldi M, Bareggi SR (2003) Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 23:660\u2013664","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jat\/16.1.54","volume":"16","author":"JE Meeker","year":"1992","unstructured":"Meeker JE, Herrmann PW, Som CW, Reynolds PC (1992) Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril. J Anal Toxicol 16:54\u201356","journal-title":"J Anal Toxicol"},{"issue":"Suppl","key":"2922_CR71","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1007\/BF00442563","volume":"99","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 99(Suppl):S68\u2013S72","journal-title":"Psychopharmacology (Berl)"},{"key":"2922_CR72","first-page":"23","volume":"52","author":"DD Miller","year":"1991","unstructured":"Miller DD (1991) Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 52:23\u201325","journal-title":"J Clin Psychiatry"},{"key":"2922_CR73","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4088\/JCP.v68n1115","volume":"68","author":"TA Moore","year":"2007","unstructured":"Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller D, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68:1751\u20131762","journal-title":"J Clin Psychiatry"},{"key":"2922_CR74","unstructured":"National Institute for Health and Clinical Experience (NICE) (2009) NICE clinical guideline 82\u2014schizophrenia."},{"key":"2922_CR75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","volume":"123","author":"J Nielsen","year":"2011","unstructured":"Nielsen J, Damkier P, Lublin H, Taylor D (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411\u2013422","journal-title":"Acta Psychiatr Scand"},{"key":"2922_CR76","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/00003088-199834060-00005","volume":"34","author":"OV Olesen","year":"1998","unstructured":"Olesen OV (1998) Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clin Pharmacokinet 34:497\u2013502","journal-title":"Clin Pharmacokinet"},{"key":"2922_CR77","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF02246112","volume":"117","author":"OV Olesen","year":"1995","unstructured":"Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen NA, Refshammer C, Sorensen J, Bysted M, Christensen J, Rosenberg R (1995) Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology (Berl) 117:371\u2013378","journal-title":"Psychopharmacology (Berl)"},{"key":"2922_CR78","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1212\/01.CON.0000368216.09706.6b","volume":"16","author":"BW Palmer","year":"2010","unstructured":"Palmer BW, Loughran CI, Meeks TW (2010) Cognitive impairment among older patients with late-life schizophrenia or bipolar disorder. Continuum Lifelong Learning Neurol 16:135\u2013152","journal-title":"Continuum Lifelong Learning Neurol"},{"key":"2922_CR79","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1192\/bjp.bp.107.042895","volume":"192","author":"C Paton","year":"2008","unstructured":"Paton C, Barnes TR, Cavanagh MR, Taylor D, Lelliott P (2008) High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 192:435\u2013439","journal-title":"Br J Psychiatry"},{"key":"2922_CR80","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clinbiochem.2008.01.020","volume":"41","author":"E Paz","year":"2008","unstructured":"Paz E, Bouzas L, Hermida J, Brenlla J, Tutor JC (2008) Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clin Biochem 41:603\u2013606","journal-title":"Clin Biochem"},{"key":"2922_CR81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1176\/ajp.148.10.1406-b","volume":"148","author":"PJ Perry","year":"1991","unstructured":"Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231\u2013235","journal-title":"Am J Psychiatry"},{"key":"2922_CR82","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/070674370805301005","volume":"53","author":"L Petersen","year":"2008","unstructured":"Petersen L, Thorup A, Oqhlenschlaeger J, Christensen TO, Jeppesen P, Krarup G, Jorrgensen P, Mortensen EL, Nordentoft M (2008) Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry 53:660\u2013670","journal-title":"Can J Psychiatry"},{"key":"2922_CR83","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e3181acd20b","volume":"29","author":"B Pfuhlmann","year":"2009","unstructured":"Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, Deckert J, Jabs B (2009) Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 29:392\u2013394","journal-title":"J Clin Psychopharmacol"},{"issue":"B","key":"2922_CR84","first-page":"94","volume":"55","author":"SC Piscitelli","year":"1994","unstructured":"Piscitelli SC, Frazier JA, McKenna K, Albus KE, Grothe DR, Gordon CT, Rapoport JL (1994) Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 55(B):94\u201397","journal-title":"J Clin Psychiatry"},{"issue":"B","key":"2922_CR85","first-page":"133","volume":"55","author":"SG Potkin","year":"1994","unstructured":"Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B et al (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55(B):133\u2013136","journal-title":"J Clin Psychiatry"},{"key":"2922_CR86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00228-002-0486-x","volume":"58","author":"K Raaska","year":"2002","unstructured":"Raaska K, Raitasuo V, Arstila M, Neuvonen PJ (2002) Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol 58:321\u2013322","journal-title":"Eur J Clin Pharmacol"},{"key":"2922_CR87","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/157488611797579230","volume":"6","author":"M Raja","year":"2011","unstructured":"Raja M (2011) Clozapine safety, 35\u00a0years later. Curr Drug Saf 6:164\u2013184","journal-title":"Curr Drug Saf"},{"key":"2922_CR88","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00007691-199802000-00017","volume":"20","author":"D Reith","year":"1998","unstructured":"Reith D, Monteleone JP, Whyte IM, Ebelling W, Holford NH, Carter GL (1998) Features and toxicokinetics of clozapine in overdose. Ther Drug Monit 20:92\u201397","journal-title":"Ther Drug Monit"},{"key":"2922_CR89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000319813","volume-title":"Therapy-resistant schizophrenia","author":"G Remington","year":"2010","unstructured":"Remington G (2010) Augmenting clozapine response in treatment-resistant schizophrenia. In: Meltzer HY, Elkis H (eds) Therapy-resistant schizophrenia. Karger, Basel, pp 129\u2013151"},{"key":"2922_CR90","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/00023210-200519100-00004","volume":"19","author":"G Remington","year":"2005","unstructured":"Remington G, Saha A, Chong SA, Shammi C (2005) Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 19:843\u2013872","journal-title":"CNS Drugs"},{"key":"2922_CR91","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/JCP.0b013e3181faa7e3","volume":"30","author":"G Sani","year":"2010","unstructured":"Sani G, Kotzalidis GD, Simonetti A, Solfanelli A, Mancinelli I, Calabro G, De Rossi P, De Luca O, Gentile G, Lionetto L, Manfredi G, Girardi N, Ambrosi E, Simmaco M, Tatarelli R (2010) Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1\u00a0F\/1F genotype. J Clin Psychopharmacol 30:737\u2013739","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004714-200202000-00015","volume":"22","author":"A Sartorius","year":"2002","unstructured":"Sartorius A, Hewer W, Zink M, Henn FA (2002) High-dose clozapine intoxication. J Clin Psychopharmacol 22:91\u201392","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR93","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003088-200342070-00001","volume":"42","author":"P Schulte","year":"2003","unstructured":"Schulte P (2003) What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 42:607\u2013618","journal-title":"Clin Pharmacokinet"},{"key":"2922_CR94","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/11587240-000000000-00000","volume":"50","author":"E Schwenger","year":"2011","unstructured":"Schwenger E, Dumontet J, Ensom MH (2011) Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clin Pharmacokinet 50:415\u2013428","journal-title":"Clin Pharmacokinet"},{"key":"2922_CR95","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FTD.0b013e3182126d83","volume":"33","author":"K Seto","year":"2011","unstructured":"Seto K, Dumontet J, Ensom MH (2011) Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit 33:275\u2013283","journal-title":"Ther Drug Monit"},{"key":"2922_CR96","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1176\/ajp.135.12.1585","volume":"135","author":"GM Simpson","year":"1978","unstructured":"Simpson GM, Cooper TA (1978) Clozapine plasma levels and convulsions. Am J Psychiatry 135:99\u2013100","journal-title":"Am J Psychiatry"},{"key":"2922_CR97","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.4088\/JCP.09r05060gre","volume":"71","author":"A Sparshatt","year":"2010","unstructured":"Sparshatt A, Taylor D, Patel MX, Kapur S (2010) A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 71:1447\u20131456","journal-title":"J Clin Psychiatry"},{"key":"2922_CR98","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.09r05739yel","volume":"72","author":"A Sparshatt","year":"2011","unstructured":"Sparshatt A, Taylor D, Patel MX, Kapur S (2011) Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 72:1108\u20131123","journal-title":"J Clin Psychiatry"},{"key":"2922_CR99","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/chi.0b013e31812eed10","volume":"46","author":"AL Sporn","year":"2007","unstructured":"Sporn AL, Vermani A, Greenstein DK, Bobb AJ, Spencer EP, Clasen LS, Tossell JW, Stayer CC, Gochman PA, Lenane MC, Rapoport JL, Gogtay N (2007) Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 46:1349\u20131356","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2922_CR100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-199602000-00021","volume":"16","author":"I Stevens","year":"1996","unstructured":"Stevens I, Gaertner HJ (1996) Plasma level measurement in a patient with clozapine intoxication. J Clin Psychopharmacol 16:86\u201387","journal-title":"J Clin Psychopharmacol"},{"key":"2922_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","volume":"107","author":"TS Stroup","year":"2009","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK (2009) Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107:1\u201312","journal-title":"Schizophr Res"},{"key":"2922_CR102","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-2007-979221","volume":"32","author":"A Szegedi","year":"1999","unstructured":"Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148\u2013153","journal-title":"Pharmacopsychiatry"},{"key":"2922_CR103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pnpbp.2005.06.011","volume":"30","author":"A Takano","year":"2006","unstructured":"Takano A, Suhara T, Kusumi I, Takahashi Y, Asai Y, Yasuno F, Ichimiya T, Inoue M, Sudo Y, Koyama T (2006) Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry 30:75\u201381","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2922_CR104","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","volume":"100","author":"R Tandon","year":"2008","unstructured":"Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100:20\u201338","journal-title":"Schizophr Res"},{"key":"2922_CR105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.v64n0107","volume":"64","author":"DM Taylor","year":"2003","unstructured":"Taylor DM, Young C, Paton C (2003) Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 64:30\u201334","journal-title":"J Clin Psychiatry"},{"key":"2922_CR106","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0447.1977.tb00148.x","volume":"55","author":"M Thorup","year":"1977","unstructured":"Thorup M, Fog R (1977) Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors. Acta Psychiatr Scand 55:123\u2013126","journal-title":"Acta Psychiatr Scand"},{"key":"2922_CR107","first-page":"133","volume":"153","author":"B Trappler","year":"1996","unstructured":"Trappler B, Kwong V, Leeman CP (1996) Therapeutic effect of clozapine at an unusually high plasma level. Am J Psychiatry 153:133\u2013134","journal-title":"Am J Psychiatry"},{"key":"2922_CR108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00007691-200006000-00015","volume":"22","author":"DR Uges","year":"2000","unstructured":"Uges DR, Boom K, Wientjes GD, Versteege J (2000) Therapeutic drug monitoring of clozapine: an unexpected outcome. Ther Drug Monit 22:323\u2013324","journal-title":"Ther Drug Monit"},{"key":"2922_CR109","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-200304000-00019","volume":"25","author":"S Ulrich","year":"2003","unstructured":"Ulrich S, Wolf R, Staedt J (2003) Serum level of clozapine and relapse. Ther Drug Monit 25:252\u2013255","journal-title":"Ther Drug Monit"},{"key":"2922_CR110","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1176\/ajp.153.12.1579","volume":"153","author":"C Zwaag van der","year":"1996","unstructured":"van der Zwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB (1996) Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153:1579\u20131584","journal-title":"Am J Psychiatry"},{"key":"2922_CR111","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1345\/aph.1K662","volume":"42","author":"AJ Wheeler","year":"2008","unstructured":"Wheeler AJ (2008) Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 42:852\u2013860","journal-title":"Ann Pharmacother"},{"key":"2922_CR112","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/070674370705200708","volume":"52","author":"J Wong","year":"2007","unstructured":"Wong J, Delva N (2007) Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 52:457\u2013463","journal-title":"Can J Psychiatry"},{"key":"2922_CR113","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2005.10.008","volume":"30","author":"JO Wong","year":"2006","unstructured":"Wong JO, Leung SP, Mak T, Ng RM, Chan KT, Hon-Kee Cheung H, Choi WK, Lai J, Wai-Kiu Tsang A (2006) Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 30:251\u2013264","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2922_CR114","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YIC.0b013e32819f8f17","volume":"22","author":"B Yusufi","year":"2007","unstructured":"Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, Barnes TR (2007) Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 22:238\u2013243","journal-title":"Int Clin Psychopharmacol"},{"key":"2922_CR115","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1124\/dmd.108.023671","volume":"36","author":"WV Zhang","year":"2008","unstructured":"Zhang WV, D\u2019Esposito F, Edwards RJ, Ramzan I, Murray M (2008) Interindividual variation in relative CYP1A2\/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab Dispos 36:2547\u20132555","journal-title":"Drug Metab Dispos"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2922-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-012-2922-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-012-2922-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T19:06:41Z","timestamp":1714590401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-012-2922-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,22]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1007\/s00213-012-2922-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,22]]}}}